ArticleACS omega2026
CustomKinFragLib: Filtering the Kinase-Focused Fragmentation Library.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Natural Product-like Fragments Unlock Novel Chemotypes for a Kinase Target─Exploring Options beyond the Flatland.Journal of chemical information and modeling · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein kinases play a crucial role in key regulatory cell processes and are known to be dysregulated in diseases such as cancer and autoimmune disorders. Hence, protein kinases represent a vital drug target class. To meet the challenge of designing novel kinase inhibitors, fragment-based drug discovery (FBDD) has already shown great promise. The kinase-specific fragment library KinFragLib is a data-driven FBDD approach providing a powerful subpocket-specific framework for creating potentially feasible kinase inhibitors through subpocket-guided enumeration and combination of fragments. However, traversing the whole recombination space is computationally infeasible. Here, we introduce CustomKinFragLib, a curation-focused and user-oriented pipeline that builds on the existing KinFragLib framework. Building on the underlying fragmentation methodology, CustomKinFragLib contributes a systematic post hoc reduction and filtering strategy to generate a smaller, more tractable, and synthesis-friendly fragment set. The pipeline integrates literature-derived drug-relevant filters, including assessments of synthetic accessibility, matching to commercially available building blocks, and availability of retrosynthetic pathways. It also considers molecular properties often associated with drug-likeness and removes fragments containing unwanted substructures. Applying these curated filters reduces the original KinFragLib from 9131 to 837 fragments while retaining diverse fragments with drug-like properties and high synthetic tractability, and providing a practical fragment set suitable for downstream design workflows. Our pipeline is easily customizable, allowing for modifications or exclusion of filters based on the user's preferences. The code and data set are available at https://github.com/volkamerlab/KinFragLib.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.